State of Michigan Retirement System Sells 10,800 Shares of Gilead Sciences, Inc. $GILD

Key Points

• State of Michigan Retirement System trimmed its Gilead stake by 3.2%, selling 10,800 shares and leaving it with 324,795 shares valued at about $39.9 million.
• Insider selling has been notable recently: the CFO and another insider each sold 3,000 shares at $140.96 under 10b5‑1 plans, and insiders have sold 178,640 shares (~$26.7M) in the past 90 days.
• Gilead increased its quarterly dividend to $0.82 (annualized $3.28, ~2.5% yield), while analysts maintain a "Moderate Buy" consensus with an average price target of $157.35.

State of Michigan Retirement System reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 324,795 shares of the biopharmaceutical company's stock after selling 10,800 shares during the quarter. State of Michigan Retirement System's holdings in Gilead Sciences were worth $39,865,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GILD. Corundum Trust Company INC bought a new stake in Gilead Sciences in the third quarter valued at $26,000. Financial Consulate Inc. lifted its position in shares of Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 109 shares during the period. MTM Investment Management LLC boosted its stake in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 176 shares in the last quarter. BOCHK Asset Management Ltd purchased a new position in shares of Gilead Sciences during the fourth quarter valued at about $31,000. Finally, Millstone Evans Group LLC raised its stake in Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 118 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the completion of the transaction, the chief financial officer directly owned 176,191 shares of the company's stock, valued at approximately $24,835,883.36. The trade was a 1.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the transaction, the insider owned 128,779 shares in the company, valued at approximately $18,152,687.84. This represents a 2.28% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 178,640 shares of company stock worth $26,691,550. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Price Performance

GILD stock opened at $130.40 on Monday. The business has a 50 day moving average of $142.44 and a 200 day moving average of $132.22. The firm has a market cap of $161.86 billion, a PE ratio of 19.26, a price-to-earnings-growth ratio of 1.72 and a beta of 0.39. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the previous year, the company posted $1.90 earnings per share. The company's revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 8.62 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were given a dividend of $0.82 per share. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences's payout ratio is currently 48.45%.

Analyst Ratings Changes

Several research firms have weighed in on GILD. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. Sanford C. Bernstein restated an "outperform" rating and issued a $160.00 target price on shares of Gilead Sciences in a research note on Wednesday, February 11th. Citigroup upped their price target on Gilead Sciences from $156.00 to $165.00 and gave the stock a "buy" rating in a research note on Monday, April 13th. TD Cowen raised their price objective on Gilead Sciences from $145.00 to $160.00 and gave the company a "buy" rating in a research report on Wednesday, February 11th. Finally, Wolfe Research upped their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an "outperform" rating in a research report on Thursday, February 12th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $157.35.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.